10%Respiratory, thoracic and mediastinal disorders - Other, Epiglottitis
10%Portal vein thrombosis
This histogram enumerates side effects from a completed 2017 Phase 2 trial (NCT01807598) in the Brentuximab Vedotin ARM group. Side effects include: Fatigue with 40%, Neutropenia with 30%, Dyspnea with 20%, Anorexia with 20%, Cough with 20%.
1 Treatment Group
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Brentuximab vedotin · No Placebo Group · Phase 2
Experimental Group · 1 Intervention: Brentuximab vedotin · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2
Screening: ~3 weeks
Reporting: through study completion, an average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
2004First Recorded Clinical Trial
8 TrialsResearching Mycosis Fungoides
520 CompletedClinical Trials
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Patients with relapsed/refractory mycosis fungoides, who have ever expressed or currently express at least 1% CD30 assessed by biopsy within 6 months prior to study enrollment, are eligible.
You have previously received systemic anticancer therapy.
You are eligible for the test if you are at least 18 years of age.
You have a performance status score of ≤ 3 (APPENDIX 5).
You are HIV positive and you are on stable antiretroviral treatment.
You are able to understand the nature and risks of the study and are willing to sign a written informed consent document.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.